Stem Nova Network at Soccerex Miami 2026: Bringing Verified Biologics to Professional Football

The first biologics partner built for professional sport.

This week, Stem Nova Network is on the ground at Soccerex Miami 2026 — the global football industry’s premier business conference — taking place September 23–25 at Nu Stadium, Inter Miami CF’s 26,700-seat venue in the heart of Miami Freedom Park. We’re here with one message: Regenerative medicine is coming to football. We’re how it gets there.

Soccerex marks its 30th anniversary this year, and it arrives at a pivotal moment. Fresh off a historic FIFA World Cup hosted across the United States, Mexico, and Canada, the North American football market is experiencing an unprecedented surge of investment, infrastructure, and commercial attention. For a regenerative biologics company focused on athlete recovery and longevity, there is no better room to be in.

Your Players Are Your Biggest Investment

Clubs invest millions in player contracts. Transfer fees, salaries, development pipelines — the financial commitment is enormous. But ask most club executives what they’re doing to protect that investment off the pitch, and the answer gets thin fast.

Player availability drives everything: match results, league positioning, sponsorship value, season ticket renewals. When a key player is unavailable, the cost isn’t just medical — it’s commercial. Yet most organizations still manage player wellness the same way they did a decade ago, with the same limited set of tools.

That gap — between the scale of the investment and the scope of the support infrastructure — is exactly why we’re at Soccerex. Regenerative biologics represent a new category of tools for the licensed physicians who manage professional athletes, and the clubs and organizations that rely on them need a supplier they can verify, audit, and trust.

What Stem Nova Actually Does

Stem Nova Network is a regenerative medicine company that partners with professional sports organizations, clubs, and athlete management groups to integrate verified biologics into their medical programs — under physician direction, with full documentation and regulatory compliance at every step.

We supply wholesale access to cGTP-compliant (21 CFR Part 1271) regenerative biologics for the licensed medical professionals who provide care to athletes. Every product we ship carries documentation that practitioners can actually audit:

• Dual-lab Certificates of Analysis (COA) — independently verified, lot-specific testing from two separate laboratories
• NTA-verified particle counts — Nanoparticle Tracking Analysis performed on final shipped product, not just production samples
• cGTP compliance (21 CFR Part 1271) — the correct regulatory framework for HCT/Ps, not cGMP
• AATB accreditation — Wharton’s jelly tissue source from an AATB-accredited establishment with this tissue category within the scope of accreditation
• FDA-registered facility with state licensure
• Post-thaw viability exceeding 90%, verified by flow cytometry with ISCT-standard markers (CD90, CD166)

These aren’t marketing claims. They’re verifiable quality benchmarks — and they are exactly what a club’s medical staff should be requiring from any biologics supplier they evaluate.

Why Professional Sport Is the Right Place

Professional sports organizations operate under extraordinary scrutiny. Every decision around player management is documented, reviewed, and second-guessed. That level of accountability is exactly the environment where quality-verified biologics belong.

The sports medicine biologics market reached an estimated $1.88 billion in 2026, with stem cell-based products representing the fastest-growing segment at a projected 6.20% CAGR through 2031. North America commands over 40% of global market revenue. The demand is accelerating — and the organizations positioned to integrate verified, compliance-documented biologics into their medical infrastructure will be the ones leading that integration.

The Conversation at Soccerex

Soccerex isn’t a medical conference. It’s the intersection of football, business, and innovation — where club executives, league commissioners, investors, brand partners, and technology companies converge to shape the next era of the sport.

This year’s agenda spans FIFA World Cup legacy planning, MLS’s next decade, football investment strategy, stadium infrastructure, media rights, and the commercial growth of women’s football through the dedicated HerSoccerex programming track. Speakers include Alexi Lalas (FOX Sports), Heidi Pellerano (Concacaf), Ali Curtis (MLS), Paul Barber (Brighton & Hove Albion), and Jürgen Mainka (FIFA World Cup 2026 Mexico Host Committee), among others.

We’re at Soccerex because the decision-makers in this room — the people responsible for long-term athlete management, facility investment, and commercial partnerships — are the same people who need to understand what verified regenerative biologics can bring to their organization’s medical infrastructure.

What the First Conversation Looks Like

If you’re a club executive, medical director, or athlete management group watching this and thinking “we should be looking at this” — here’s what the first conversation looks like.

We start with your organization’s current medical infrastructure and what your licensed medical professionals are already doing. From there, we walk through our product documentation, compliance framework, and what integration under physician direction actually looks like in practice. No pressure, no pitch deck — just a transparent look at the products, the data, and the regulatory framework behind them.

Every engagement begins with the practitioner. We supply the biologics; the licensed physician makes all clinical decisions.